COMP <GO>
VRTX vs GSK // EV/EBITDA & P/E VALUATION
Vertex Pharmaceuticals Incorporated (NASDAQ) VS. GSK plc American (NYSE) • 15-METRIC TALLY: VRTX 9
— GSK 2
▲ EV/EBITDA & P/E VALUATION LEADER: GSK
LAST: $558.88 (+3.50%) • MKT CAP: $136.87B
valuation
29.6x
LAST: $49.51 (+1.71%) • MKT CAP: $98.47B
valuation
21.0x
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (VRTX VS. GSK)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | VRTX | GSK | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 86.20% | — | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 20.00% | 9.90% | +10.10 | VRTX | /roic <GO> |
| EV/EBITDA & P/E Valuation ACTIVE | 29.6x | 21.0x | +8.60 | GSK | /valuation <GO> |
| Free Cash Flow Yield | 2.33% | 2.21% | +0.12 | VRTX | /fcf-yield <GO> |
| Operating Margin | 34.80% | 13.90% | +20.90 | VRTX | /operating-margins <GO> |
| Net Profit Margin | 32.90% | 10.90% | +22.00 | VRTX | /net-margins <GO> |
| Revenue Growth (YoY) | 8.90% | 8.80% | +0.10 | VRTX | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 13.86 | 3.74 | +10.12 | VRTX | /balance-sheet <GO> |
| Piotroski F-Score Quality | 8/9 | 8/9 | 0.00 | TIE | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 57.7 | 46.8 | +10.90 | VRTX | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 1.02 | 0.95 | +0.07 | VRTX | /macro-sensitivity <GO> |
| Forward P/E Multiple | 32.2x | 30.5x | +1.70 | GSK | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $136.87B | $98.47B | $38.40B | VRTX | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | VRTX REV | GSK REV | VRTX GROSS % | GSK GROSS % | VRTX FCF | GSK FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $12.00B | — | 86.2% | — | $3.19B | — |
| FY 2024 | $11.02B | — | 86.1% | — | -$790.3M | — |
| FY 2023 | $9.87B | — | — | — | $3.09B | — |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
VRTX // BETA 1.02
GSK // BETA 0.95